Literature DB >> 18559805

Pharmacologic mechanisms of crystal meth.

Stephen J Kish1.   

Abstract

Crystal meth is a form of the stimulant drug methamphetamine that, when smoked, can rapidly achieve high concentrations in the brain. Methamphetamine causes the release of the neurotransmitters dopamine, norepinephrine and serotonin and activates the cardiovascular and central nervous systems. The levels of dopamine are low in the brain of some drug users, but whether this represents neuronal loss is uncertain. The areas of the brain involved in methamphetamine addiction are unknown but probably include the dopamine-rich striatum and regions that interact with the striatum. There is no medication approved for the treatment of relapses of methamphetamine addiction; however, potential therapeutic agents targeted to dopamine and nondopamine (e.g., opioid) systems are in clinical testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559805      PMCID: PMC2413312          DOI: 10.1503/cmaj.071675

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  33 in total

Review 1.  A new anatomical framework for neuropsychiatric disorders and drug abuse.

Authors:  Lennart Heimer
Journal:  Am J Psychiatry       Date:  2003-10       Impact factor: 18.112

2.  Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

Authors:  David Michelson; Albert J Allen; Joan Busner; Charles Casat; David Dunn; Christopher Kratochvil; Jeffrey Newcorn; F Randy Sallee; R Bart Sangal; Keith Saylor; Scott West; Douglas Kelsey; Joachim Wernicke; Nancy J Trapp; Donald Harder
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

3.  Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.

Authors:  R B Rothman; M H Baumann; C M Dersch; D V Romero; K C Rice; F I Carroll; J S Partilla
Journal:  Synapse       Date:  2001-01       Impact factor: 2.562

4.  Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence.

Authors:  J Shearer; A Wodak; R P Mattick; I Van Beek; J Lewis; W Hall; K Dolan
Journal:  Addiction       Date:  2001-09       Impact factor: 6.526

Review 5.  Treatment of methamphetamine use disorders: an update.

Authors:  Richard A Rawson; Rachel Gonzales; Paul Brethen
Journal:  J Subst Abuse Treat       Date:  2002-09

6.  Clinical effects of methamphetamine vapor inhalation.

Authors:  M Perez-Reyes; W R White; S A McDonald; J M Hill; A R Jeffcoat; C E Cook
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

Review 7.  The epidemiology of methamphetamine use and harm in Australia.

Authors:  Louisa Degenhardt; Amanda Roxburgh; Emma Black; Raimondo Bruno; Gabrielle Campbell; Stuart Kinner; James Fetherston
Journal:  Drug Alcohol Rev       Date:  2008-05

8.  Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.

Authors:  James J McGough; Joseph Biederman; Laurence L Greenhill; James T McCracken; Thomas J Spencer; Kelly Posner; Sharon Wigal; Jeffrey Gornbein; Simon Tulloch; James M Swanson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-06       Impact factor: 8.829

Review 9.  Monoamine transporters and psychostimulant drugs.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2003-10-31       Impact factor: 4.432

10.  Why is parkinsonism not a feature of human methamphetamine users?

Authors:  Anna Moszczynska; Paul Fitzmaurice; Lee Ang; Kathryn S Kalasinsky; Gregory A Schmunk; Frank J Peretti; Sally S Aiken; Dennis J Wickham; Stephen J Kish
Journal:  Brain       Date:  2003-11-25       Impact factor: 13.501

View more
  45 in total

1.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

Review 2.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

Review 3.  Effects of prenatal methamphetamine exposure: a review of cognitive and neuroimaging studies.

Authors:  Maja A Kwiatkowski; Annerine Roos; Dan J Stein; Kevin G F Thomas; Kirsty Donald
Journal:  Metab Brain Dis       Date:  2013-12-28       Impact factor: 3.584

4.  Limiting production of crystal meth.

Authors:  Joseph Caplan
Journal:  CMAJ       Date:  2008-09-09       Impact factor: 8.262

5.  A question of ethics.

Authors:  Mark Dubé
Journal:  CMAJ       Date:  2008-09-09       Impact factor: 8.262

6.  Dopamine D1 receptor activation induces dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cells.

Authors:  Jiao-Jiao Xu; Si-Yuan Wang; Ye Chen; Guang-Ping Chen; Zai-Quan Li; Xue-Yan Shao; Liang Li; Wei Lu; Tian-Yan Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150

Review 7.  Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Authors:  Stephen J Kish; Isabelle Boileau; Russell C Callaghan; Junchao Tong
Journal:  Eur J Neurosci       Date:  2016-09-05       Impact factor: 3.386

Review 8.  Methamphetamine and the risk of pulmonary arterial hypertension.

Authors:  Ramon L Ramirez; Vinicio De Jesus Perez; Roham T Zamanian
Journal:  Curr Opin Pulm Med       Date:  2018-09       Impact factor: 3.155

9.  PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.

Authors:  Emily E Reichard; Nisha Nanaware-Kharade; Guillermo A Gonzalez; Shraddha Thakkar; S Michael Owens; Eric C Peterson
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

10.  Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.

Authors:  Isabelle Boileau; Tina McCluskey; Junchao Tong; Yoshiaki Furukawa; Sylvain Houle; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2015-08-31       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.